Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: shortened trading session ends week

November 25, 2022 7:49am

Closing trading at 1 p.m.; month’s end – Wednesday of next week

Indications: 1 Sell into Strength, 1 positive Indication and 1 Negative Indication

A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.

I don’t seek fame, do podcasts or give speeches; what I do is write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are UP +0.20% or (+69 points), S&P futures are UP +0.14% or (+5 points) and NASDAQ futures are DOWN -0.16% or (-19 points) early in the pre-open – so far,

U.S. stock futures inched cautiously higher on Friday,

European markets were subdued,

Asia-Pacific markets were mostly lower.

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed higher Wednesday in a choppy session as meeting minutes from the Fed is looking to hand out … smaller rate hikes… in the coming months as inflation cools off.

The Dow closed UP +95.96 points (+0.28%), the S&P close UP +23.69 points (+0.59%) while the Nasdaq closed UP +110.91 points (+0.99%)

Markets were closed on Thursday for the Thanksgiving holiday and will close at 1 p.m. ET on Friday.

Wednesday’s (11/22) … RegMed Investors’ (RMi) closing bell: “gobble, gobble; share pricing heated-up. Gotta go, be safe in any holiday endeavor.” … https://www.regmedinvestors.com/articles/12714

Ebb and flow:

Q4 – November - 1 holiday, 11 negative and 7 positive closes

· October -1 neutral, 11 positive and 9 negative closes

Q3/22 –

· September – 1 holiday, 10 positive and 11 negative closes

· August – 1 neutral, 11 positive and 11 negative closes

· July - 1 holiday, 10 negative and 10 positive closes

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Positive indication:

CRISPR Therapeutics (CRSP) closed down -$0.43 to $55.03 with a positive +$0.47 or +0.85% pre-open indication,

Sell into Strength:

uniQure NV (QURE) closed up +$3.36 to $26.36 with a positive +$0.78 or +2.96% pre-open indication.

Negative Indication;

Alnylam Pharmaceuticals (ALNY) closed down -$0.92 to $208.49 with a negative -$5.51 or -$2.64% pre-open indication.

The BOTTOM LINE: I try to keep it simple … and short while repeating what I did write last night!

Thanksgiving is over to some extent except for travel, light trading volume and full refrigerators.

Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.

Reiterating, “The real question that should be asked is how many companies are at the end of sentiments … leash? I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”.

Insight is about understanding perception and also about putting into context what is relevant to expectation fulfillment

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.